ISTH 2020 Congress
Coagulation and Natural Anticoagulants » Coagulation Factors and Inhibitors
Theme Navigation
- ISTH 2020 Congress
- Coagulation and Natural Anticoagulants
- Coagulation Factors and Inhibitors
- Coagulation and Natural Anticoagulants
Abstract Number: PB0201
A Comparison of Mass and Potency Equated Bovine and Porcine Heparins
Abstract Number: PB0189
A Double Heterozygous Factor VII (FVII) Deficiency: Exon 9 Missense Mutation (Arg364Gln – FVII Padua) and a Novel Exon 3 Missense Mutation (Ala87Gly)
Abstract Number: PB0223
A Novel Coagulation Factor VIII with Reduced Immunogenicity
Abstract Number: PB0169
A Novel Prediction Platform to Enhance the Design of Therapeutic SERPINs
Abstract Number: PB0158
A Novel Rare C. – 39C>T Mutation in the PROS1 5’UTR Causes Protein S Deficiency by Creating a New Upstream Translation Initiation Codon and an Overlapping Open Reading frame
Abstract Number: PB0224
A Sensitive and Specific Assay to Measure TF Activity in Cell-derived Extracellular Vesicles Based on Thrombin Generation
Abstract Number: PB0162
Acquired Haemophilia Spanish Registry, First Five Years of Activity
Abstract Number: PB0154
Activated recombinant Factor VII (rFVIIa) Inhibitor in Iran: Immunogenicity is a Major Challenge through Treated Bleeds Covered with rFVIIa
Abstract Number: PB0227
Addition of Histone Deacetylase Inhibitors Increases Recombinant Factor V Expression in BHK Cells
Abstract Number: PB0239
Always Ask Relevant Questions to Patients Might Be They Tell You the Diagnosis
Abstract Number: PB0226
Anti-factor V Inhibitor after Liver Transplantation
Abstract Number: PB0213
Anticoagulant Effect of Novel Nanoparticles Functionalized with Synthetic Piperazinone Derivatives as FXa Inhibitors
Abstract Number: PB0182
Anticoagulant Effects of Parenteral Sulodexide as Measured by Activated Clotting Time. Relevance to Dosing in Various Indications
Abstract Number: PB0166
Anticoagulation with the Novel, Small-molecule Factor XIa (fXIa) Antagonist, EP-7041, Prevents Oxygenator Clotting but Conserves Hemostasis in a Canine Extracorporeal Circulation (ECMO) Model
Abstract Number: PB0179
Antithrombotic Effects of a Novel Small Molecular Fxia Inhibitor BMS-986177/JNJ-70033093 in a Rabbit AV-Shunt Model of Thrombosis
Abstract Number: PB0219
Are the Plasma Levels Thresholds of DOAC Rationale and Appropriate for Clinical Decision-making? A Reappraisal Using Thrombin Generation Testing
Abstract Number: PB0236
Assessment of Four Factor Prothrombin Complex Concentrate (4F-PCC) Usage in Emergency Department Patients: A Single Center Experience
Abstract Number: PB0234
Baseline VWF Antigen Level Is Associated with the Outcome of Immune Tolerance Induction Using pdFVIII/VWF Concentrate in Hemophilia A with Inhibitor